Clinical trials
Completed Observational Diabetic Nephropathies trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 2 |
| 2013 | 3 |
| 2014 | 7 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 3 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 45 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 4 |
| Tanta University | 2 |
| University of Colorado, Denver | 2 |
| University of Sao Paulo General Hospital | 2 |
| Aarhus University Hospital | 1 |
| Arkansas Children's Hospital Research Institute | 1 |
| Assiut University | 1 |
| Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | 1 |
| Beijing Tongren Hospital | 1 |
| Benha University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetic Nephropathies | 45 |
| Diabetes Mellitus, Type 2 | 13 |
| Diabetes Mellitus | 6 |
| Kidney Diseases | 6 |
| Diabetes Mellitus, Type 1 | 5 |
| Renal Insufficiency, Chronic | 5 |
| Obesity | 4 |
| Proteinuria | 4 |
| Diabetes Complications | 3 |
| Glomerulonephritis, IGA | 2 |
Trials
Showing 1 to 25 of 45. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.